Table 2.

Clinicopathologic characteristics in patients with progression

PDP
No (n = 26)Yes (n = 6)
Age, median (range)52 (21–76)59 (52–71)0.049*
Sex
    Male18 (90%)2 (10%)0.17
    Female8 (66.7%)4 (33.3%)—
Race
    White24 (82.8%)5 (17.2%)0.48
    Black0 (0%)1 (100%)—
    Hispanic1 (100%)0 (0%)—
    Asian1 (100%)0 (0%)—
Smoking status
    Never smoker12 (92.3%)1 (7.7%)0.17
    Former smoker8 (88.9%)1 (11.1%)—
    Current smoker6 (60%)4 (40%)—
Differentiation
    Well1 (100%)0 (0%)0.70
    Moderate7 (87.5%)1 (12.5%)—
    Poorly11 (84.6%)2 (15.4%)—
    Moderately well1 (50%)1 (50%)—
    Poorly moderately2 (100%)0 (0%)—
T stage
    T1–T218 (86%)3 (14%)0.003
    T3–T48 (73%)3 (27%)—
N stage
    N2B19 (90.5%)2 (9.5%)0.090
    N2C5 (62.5%)3 (37.5%)—
    N31 (50%)1 (50%)—
EGFR†
    00 (0%)0 (0%)0.78
    1+4 (100%)0 (0%)
    2+5 (100%)0 (0%)
    3+37 (82.2%)8 (17.8%)
HPV‡
    HPV positive12 (100%)0 (0%)0.008
    HPV negative8 (57%)6 (43%)

  • ↵*P value from Wilcoxon rank sum test; all other P values were from Fisher's exact test.

  • ↵†Available for 24 patients.

  • ↵‡Available for 26 patients.